We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has approved AbbVie’s Mavyret (glecaprevir and pibrentasvir), the first drug to treat all six genotypes of Hepatitis C virus (HCV), for children with the condition aged between 12 and 17.
The label for Eli Lilly and Company's once-weekly Trulicity® (dulaglutide) is now updated to include use in combination with basal insulin for adults with type 2 diabetes.